Michael Yamamoto

Parse Biosciences

Parse Biosciences is a Seattle-based startup providing researchers access to the most scalable single cell sequencing platform available. With technology founded on the principles of SPLiT-seq, published in Science in 2018, Parse Biosciences' mission is to accelerate progress in scientific research as well as human health. Single-cell sequencing has already enabled groundbreaking discoveries that have led to new understandings in cancer treatment, tissue repair, stem cell therapy, the immune system and much more. At Parse Biosciences we provide researchers with the ability to perform single cell sequencing with unprecedented scale and ease.